Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.50 |
| ▸ | CCKBR | P32239 | 4/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8724250 | 0.88 | LMNA (0.67) | LMNAMEN1ALBKMT2ACHRM1 | |
| SCHEMBL10098855 | 0.81 | CCKBR (0.57) | LMNAMEN1ALBKMT2ACHRM1 | |
| SCHEMBL21272235 | 0.80 | LMNA (0.71) | LMNAMEN1ALBKMT2ACHRM1 | |
| SCHEMBL10149196 | 0.78 | OPRK1 (0.57) | LMNAALBCCKBROPRK1PDE4D | |
| SCHEMBL11633050 | 0.78 | LMNA (0.79) | LMNAMEN1ALBKMT2ACHRM1 | |
| SCHEMBL9060504 | 0.77 | LMNA (0.59) | LMNAMEN1ALBKMT2ACHRM1 | |
| SCHEMBL9183388 | 0.75 | LMNA (0.67) | LMNAMEN1ALBKMT2ACHRM1 | |
| SCHEMBL11964614 | 0.75 | CCKBR (0.68) | LMNAMEN1ALBKMT2ACHRM1 | |
| SCHEMBL8726517 | 0.74 | CCKBR (0.61) | MEN1KMT2ACHRM1CCKBR | |
| SCHEMBL10203612 | 0.74 | CCKBR (0.61) | LMNAMEN1ALBKMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168626-B2 | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168626-B2 | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120077805-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
| US-7994313-B2 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994313-B2 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100222310-A1 | BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-02 | — | — | US | disclosed |
| US-20100222310-A1 | BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-02 | — | — | US | disclosed |
| US-7683046-B2 | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683046-B2 | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090253686-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253686-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-10-08 | — | — | US | disclosed |
| US-20080269203-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| US-20080269203-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| WO-2008116156-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS ASSOCIATED WITH MITOCHONDRIAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-25 | — | — | WO | disclosed |
| US-7276348-B2 | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276348-B2 | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2007053193-A2 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222310-A1 | BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS | VDR, CYP2R1, CYP24A1 | LMNA 2190/4885MEN1 4163/4885ALB 3296/4885 |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | LMNA 2704/4885MEN1 3855/4885ALB 3662/4885 |
| US-20120077805-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | GABRA5, GABRA3, GABRA6 | LMNA 1390/4885MEN1 3952/4885ALB 2710/4885 |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | GABRA5, GABRA3, GABRA6 | LMNA 1390/4885MEN1 3952/4885ALB 2710/4885 |
| US-20090253686-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | GABRA5, GABRA3, GABRA6 | LMNA 1390/4885MEN1 3952/4885ALB 2710/4885 |
| US-20080269203-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | BAX, BAD, GABRB3 | LMNA 2518/4885MEN1 4503/4885ALB 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.